The production value of pharmaceutical preparations in France has experienced significant fluctuations over the past decade. Starting at 25.22 billion Euros in 2013, the market peaked at 40.49 billion Euros in 2018 before experiencing a slight dip in 2019, followed by a steady recovery. In 2023, the production value stood at 42.45 billion Euros. The year-on-year growth rate was 2.99% in 2023, reflecting a moderate recovery trajectory after previous years of more volatile growth rates. The compound annual growth rate (CAGR) from 2018 to 2023 was 0.95%, indicating modest gains over the five-year period.
Looking at forecasted data from 2024 to 2028, the production value is projected to continue its upward trend, reaching 48.44 billion Euros by 2028. The forecasted CAGR over this period is 2.09%, suggesting a stable growth outlook with a forecasted 5-year growth rate of 10.91%. This suggests a cautiously optimistic environment for the pharmaceutical sector in France, driven by factors such as innovation in drug development, increased healthcare spending, and potential expansion in global markets.
Future trends to watch for:
- Advancements in biotechnology and personalized medicine
- Regulatory changes and their impact on the market
- Investment in R&D and its effects on production value
- Global health challenges and their influence on pharmaceutical demand
- Economic conditions and healthcare policies in France and the broader EU
